NYSE:CTLT - Catalent Stock Price, Price Target & More

Get Started

$38.86 +0.05 (+0.13 %)

(As of 05/25/2018 04:00 PM ET)

Previous Close$38.86

Today's Range$38.69 - $39.11

52-Week Range$33.42 - $47.87

Volume605,866 shs

Average Volume851,109 shs

Market Capitalization$5.18 billion

P/E Ratio28.79

Dividend YieldN/A

Beta1.53

About Catalent (NYSE:CTLT)

Catalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through three segments: Softgel Technologies, Drug Delivery Solutions, and Clinical Supply Services. The Softgel Technologies segment offers formulation, development, and manufacturing services for softgels, which are used in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, and unit-dose cosmetics. Its principal softgel technologies include traditional softgel capsules, as well as Vegicaps and OptiShell capsules. The Drug Delivery Solutions segment formulates, develops, and manufactures prescription, and consumer and animal health products using OptiMelt, OptiPact, OptiForm, and Zydis, as well as other proprietary and conventional drug delivery technologies, such as prefilled syringes; manufactures blow-fill seal unit dose consisting of ADVASEPT technology; develops biologic cell line, such as GPEx and SMARTag technologies; provides biologics; and offers analytical and bioanalytical development, and testing services. This segment also provides analytical chemical, and cell-based testing and scientific; stability testing; respiratory products formulation and manufacturing; micronization and particle engineering; regulatory consulting; and bioanalytical testing services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials; FastChain demand-led clinical supply services; clinical e-solutions and informatics; and comparator sourcing services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. Catalent, Inc. was founded in 2007 and is headquartered in Somerset, New Jersey.

Receive CTLT News and Ratings via Email

Sign-up to receive the latest news and ratings for CTLT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

SymbolNYSE:CTLT

CUSIPN/A

Webwww.catalent.com

Phone732-537-6200

Debt

Debt-to-Equity Ratio2.53

Current Ratio2.18

Quick Ratio1.78

Price-To-Earnings

Trailing P/E Ratio28.79

Forward P/E Ratio25.07

P/E Growth2.06

Sales & Book Value

Annual Sales$2.08 billion

Price / Sales2.50

Cash Flow$2.5976 per share

Price / Cash14.96

Book Value$8.01 per share

Price / Book4.85

Profitability

EPS (Most Recent Fiscal Year)$1.35

Net Income$109.80 million

Net Margins2.62%

Return on Equity21.76%

Return on Assets5.16%

Miscellaneous

Employees10,800

Outstanding Shares133,370,000

Catalent (NYSE:CTLT) Frequently Asked Questions

What is Catalent's stock symbol?

Catalent trades on the New York Stock Exchange (NYSE) under the ticker symbol "CTLT."

How were Catalent's earnings last quarter?

Catalent (NYSE:CTLT) released its quarterly earnings data on Tuesday, May, 1st. The company reported $0.41 EPS for the quarter, beating the consensus estimate of $0.35 by $0.06. The company had revenue of $627.90 million for the quarter, compared to analyst estimates of $610.47 million. Catalent had a return on equity of 21.76% and a net margin of 2.62%. The firm's revenue was up 17.9% compared to the same quarter last year. During the same period last year, the company posted $0.38 earnings per share. View Catalent's Earnings History.

What guidance has Catalent issued on next quarter's earnings?

Catalent issued an update on its FY18 earnings guidance on Tuesday, May, 1st. The company provided earnings per share guidance of $1.57-$1.74 for the period, compared to the Thomson Reuters consensus estimate of $1.67. The company issued revenue guidance of $2.42-$2.48 billion, compared to the consensus revenue estimate of $2.45 billion.

What price target have analysts set for CTLT?

14 brokers have issued 12-month target prices for Catalent's stock. Their forecasts range from $38.00 to $50.00. On average, they anticipate Catalent's stock price to reach $45.8182 in the next twelve months. View Analyst Ratings for Catalent.

Who are some of Catalent's key competitors?

Some companies that are related to Catalent include Mylan (MYL), BioMarin Pharmaceutical (BMRN), Grifols (GRFS), UCB (UCBJF), Ono Pharmaceutical (OPHLF), Nektar Therapeutics (NKTR), Genmab (GNMSF), Merck Group (MKGAF), Perrigo (PRGO), BeiGene (BGNE), Alnylam Pharmaceuticals (ALNY), Jazz Pharmaceuticals (JAZZ), Valeant Pharmaceuticals Intl (VRX), SAGE Therapeutics (SAGE) and Alkermes (ALKS).

Who are Catalent's key executives?

Catalent's management team includes the folowing people:

Mr. John R. Chiminski, Chairman, Pres & CEO (Age 54)
Mr. Steven L. Fasman Esq., Sr. VP, Gen. Counsel & Corp. Sec. (Age 55)
Mr. William Downie, Sr. VP of Global Marketing & Sales (Age 51)
Mr. Barry B. Littlejohns, Pres of Biologics & Specialty Drug Delivery (Age 52)
Mr. Wetteny N. Joseph, Sr. VP & CFO (Age 46)

Has Catalent been receiving favorable news coverage?

News stories about CTLT stock have been trending somewhat positive this week, according to Accern. The research firm identifies positive and negative news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Catalent earned a daily sentiment score of 0.14 on Accern's scale. They also assigned headlines about the company an impact score of 46.26 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

Who are Catalent's major shareholders?

Catalent's stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (11.45%), JPMorgan Chase & Co. (3.21%), Champlain Investment Partners LLC (2.72%), American Century Companies Inc. (2.15%), Earnest Partners LLC (1.90%) and Northern Trust Corp (1.52%). Company insiders that own Catalent stock include Blackstone Management Associat, Christine Dolan, Donald E Morel, Jr, John R Chiminski, Matthew M Walsh, Sharon Johnson, Uwe Roehrhoff and William Downie. View Institutional Ownership Trends for Catalent.

Which institutional investors are selling Catalent stock?

CTLT stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Millennium Management LLC, BNP Paribas Arbitrage SA, Hood River Capital Management LLC, Dimensional Fund Advisors LP, JPMorgan Chase & Co., Loomis Sayles & Co. L P and Carillon Tower Advisers Inc.. Company insiders that have sold Catalent company stock in the last year include Christine Dolan, John R Chiminski and William Downie. View Insider Buying and Selling for Catalent.

Which institutional investors are buying Catalent stock?

CTLT stock was acquired by a variety of institutional investors in the last quarter, including Champlain Investment Partners LLC, Wells Fargo & Company MN, Prudential Financial Inc., GW&K Investment Management LLC, Impax Asset Management LLC, American Century Companies Inc., Segall Bryant & Hamill LLC and Mackay Shields LLC. Company insiders that have bought Catalent stock in the last two years include Donald E Morel, Jr and Uwe Roehrhoff. View Insider Buying and Selling for Catalent.

How do I buy shares of Catalent?

Shares of CTLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Catalent's stock price today?

One share of CTLT stock can currently be purchased for approximately $38.86.

How big of a company is Catalent?

Catalent has a market capitalization of $5.18 billion and generates $2.08 billion in revenue each year. The company earns $109.80 million in net income (profit) each year or $1.35 on an earnings per share basis. Catalent employs 10,800 workers across the globe.

How can I contact Catalent?

Catalent's mailing address is 14 SCHOOLHOUSE ROAD, SOMERSET NJ, 08873. The company can be reached via phone at 732-537-6200 or via email at [email protected]

MarketBeat Community Rating for Catalent (CTLT)

Community Ranking:		2.5 out of 5 ( )
Outperform Votes:		228 (Vote Outperform)
Underperform Votes:		237 (Vote Underperform)
Total Votes:		465

MarketBeat's community ratings are surveys of what our community members think about Catalent and other stocks. Vote "Outperform" if you believe CTLT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CTLT will underperform the S&P 500 over the long term. You may vote once every thirty days.

Catalent (NYSE:CTLT) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

14 Wall Street analysts have issued ratings and price targets for Catalent in the last 12 months. Their average twelve-month price target is $45.8182, suggesting that the stock has a possible upside of 17.91%. The high price target for CTLT is $50.00 and the low price target for CTLT is $38.00. There are currently 4 hold ratings and 10 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	2.71	2.73	2.67	2.67
Ratings Breakdown:	0 Sell Rating(s) 4 Hold Rating(s) 10 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 4 Hold Rating(s) 11 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 4 Hold Rating(s) 8 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 3 Hold Rating(s) 6 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$45.8182	$45.8182	$45.3333	$41.3750
Price Target Upside:	17.91% upside	15.44% upside	6.24% upside	3.36% upside

Catalent (NYSE:CTLT) Consensus Price Target History

Price Target History for Catalent (NYSE:CTLT)

Catalent (NYSE:CTLT) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
3/28/2018	KeyCorp	Upgrade	Sector Weight ➝ Overweight	$48.00	Medium
3/21/2018	Raymond James	Upgrade	Market Perform ➝ Outperform	$48.00	High
3/21/2018	UBS	Upgrade	Market Perform ➝ Outperform		High
2/6/2018	Bank of America	Boost Price Target	Buy ➝ Buy	$47.00 ➝ $49.00	Medium
2/6/2018	Stephens	Downgrade	Overweight ➝ Equal Weight		High
2/5/2018	Royal Bank of Canada	Set Price Target	Buy	$48.00	High
1/24/2018	Goldman Sachs Group	Initiated Coverage	Buy	$50.00	High
1/5/2018	First Analysis	Initiated Coverage	Equal Weight		Low
11/7/2017	Piper Jaffray Companies	Boost Price Target	Overweight	$45.00 ➝ $50.00	N/A
10/23/2017	Needham & Company LLC	Reiterated Rating	Hold		N/A
9/21/2017	Morgan Stanley	Upgrade	Equal Weight ➝ Overweight	$29.00 ➝ $48.00	High
9/20/2017	Wells Fargo & Co	Boost Price Target	Outperform	$39.00 ➝ $43.00	Low
8/29/2017	William Blair	Reiterated Rating	Ourperform		High
8/29/2017	Jefferies Group	Reiterated Rating	Hold	$35.00 ➝ $38.00	High
8/29/2017	JPMorgan Chase & Co.	Reiterated Rating	Buy	$40.00	High

(Data available from 5/26/2016 forward)

Catalent (NYSE:CTLT) Earnings History and Estimates Chart

Earnings by Quarter for Catalent (NYSE:CTLT)

Catalent (NYSE:CTLT) Earnings Estimates

2018 EPS Consensus Estimate: $1.20
2019 EPS Consensus Estimate: $1.82

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q2 2018	1	$0.29	$0.29	$0.29
Q3 2018	2	$0.36	$0.36	$0.36
Q4 2018	2	$0.54	$0.55	$0.55
Q1 2019	1	$0.26	$0.26	$0.26
Q2 2019	2	$0.44	$0.48	$0.46
Q3 2019	2	$0.42	$0.45	$0.44
Q4 2019	1	$0.66	$0.66	$0.66

Catalent (NYSE CTLT) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/1/2018	Q3 2018	$0.35	$0.41	$610.47 million	$627.90 million	View	N/A
2/5/2018	Q2 2018	$0.31	$0.41	$565.05 million	$606.30 million	View	N/A
11/6/2017	Q1 2018	$0.20	$0.21	$490.75 million	$543.90 million	View	N/A
8/28/2017	Q4 2017	$0.57	$0.65	$547.48 million	$616.90 million	View	N/A
5/4/2017	Q3 2017	$0.36	$0.38	$470.95 million	$532.60 million	View	Listen
2/6/2017	Q217	$0.27	$0.27	$474.07 million	$483.70 million	View	Listen
11/7/2016	Q117	$0.13	$0.16	$430.26 million	$442.20 million	View	Listen
8/29/2016	Q416	$0.53	$0.52	$498.06 million	$532.20 million	View	Listen
5/4/2016	Q316	$0.31	$0.20	$425.92 million	$438.00 million	View	N/A
2/9/2016	Q216	$0.34	$0.36	$441.99 million	$454.90 million	View	N/A
11/3/2015	Q116	$0.21	$0.14	$407.80 million	$423.00 million	View	N/A
9/2/2015	Q415	$0.58	$0.60	$496.91 million	$510.10 million	View	N/A
5/5/2015	Q3 2015	$0.43	$0.46	$453.25 million	$446.60 million	View	N/A
2/11/2015	Q215	$0.33	$0.44	$451.40 million	$455.80 million	View	N/A
11/13/2014	Q314	$0.20	$0.13	$411.20 million	$418.30 million	View	N/A
9/4/2014	Q4 2014		$1.03		$519.60 million	View	N/A

(Earnings results data provided by Zacks Investment Research)

Catalent (NYSE:CTLT) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Catalent (NYSE CTLT) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 1.70%
Institutional Ownership Percentage: 99.28%

Insider Trading History for Catalent (NYSE:CTLT)

Institutional Ownership by Quarter for Catalent (NYSE:CTLT)

Catalent (NYSE CTLT) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/8/2018	William Downie	SVP	Sell	9,082	$41.80	$379,627.60	46,986
12/12/2017	John R Chiminski	Insider	Sell	181,458	$39.62	$7,189,365.96
11/21/2017	Uwe Roehrhoff	Director	Buy	7,500	$39.22	$294,150.00
8/29/2017	Christine Dolan	SVP	Sell	1,594	$38.75	$61,767.50
8/1/2017	Christine Dolan	SVP	Sell	745	$34.85	$25,963.25
4/25/2017	Sharon Johnson	Insider	Sell	9,160	$29.00	$265,640.00
3/20/2017	John R. Chiminski	Insider	Sell	73,819	$28.62	$2,112,699.78
2/15/2017	Donald E. Morel, Jr.	Director	Buy	10,000	$29.27	$292,700.00
9/9/2016	Blackstone Management Associat	Major Shareholder	Sell	17,100,705	$23.58	$403,234,623.90
6/9/2016	Blackstone Management Associat	Major Shareholder	Sell	8,785,539	$24.51	$215,333,560.89
5/27/2016	Matthew M Walsh	Insider	Sell	21,197	$28.85	$611,533.45	105,688
8/19/2015	John R Chiminski	Insider	Sell	38,505	$33.81	$1,301,854.05
8/17/2015	John R Chiminski	Insider	Sell	35,550	$33.80	$1,201,590.00
7/20/2015	John R Chiminski	Insider	Sell	33,081	$29.40	$972,581.40
7/6/2015	John R Chiminski	Insider	Sell	33,828	$29.34	$992,513.52
6/11/2015	Blackstone Management Associat	Major Shareholder	Sell	1,844,963	$28.13	$51,898,809.19
6/8/2015	Blackstone Management Associat	Major Shareholder	Sell	12,299,753	$28.13	$345,992,051.89
4/1/2015	Scott Houlton	Insider	Sell	16,253	$30.61	$497,504.33
3/27/2015	Stephen Leonard	Insider	Sell	31,005	$30.13	$934,180.65
2/17/2015	Scott Houlton	Insider	Sell	14,538	$27.50	$399,795.00
2/13/2015	Scott Houlton	Insider	Sell	1,400	$28.28	$39,592.00

(Data available from 1/1/2013 forward)

Catalent (NYSE CTLT) News Headlines

Source:

Date	Headline
	Tenant on former Marion Labs campus completes $5.5M expansion finance.yahoo.com - May 22 at 4:37 PM
	Catalent (CTLT) Receives Consensus Rating of "Buy" from Brokerages www.americanbankingnews.com - May 20 at 11:31 AM
	Wired News – Zomedica Inks Deal with Seraph to Develop and Market Seraph’s Novel Pathogen Detection System for Veterinarians finance.yahoo.com - May 14 at 9:47 AM
	Brokerages Expect Catalent (CTLT) Will Post Quarterly Sales of $690.52 Million www.americanbankingnews.com - May 13 at 4:55 AM
	Catalent (CTLT) Expected to Post Earnings of $0.60 Per Share www.americanbankingnews.com - May 11 at 5:16 AM
	Catalent (CTLT) Rating Increased to Buy at Zacks Investment Research www.americanbankingnews.com - May 10 at 8:41 PM
	Catalent, Inc. to Present at Four Upcoming Investor Conferences finance.yahoo.com - May 9 at 4:48 PM
	Catalent (CTLT) Forecasted to Earn Q3 2019 Earnings of $0.45 Per Share www.americanbankingnews.com - May 3 at 9:57 AM
	Edited Transcript of CTLT earnings conference call or presentation 1-May-18 12:15pm GMT finance.yahoo.com - May 2 at 9:06 AM
	Catalent (CTLT) Announces Quarterly Earnings Results, Beats Estimates By $0.02 EPS www.americanbankingnews.com - May 1 at 4:14 PM
	Catalent (CTLT) Releases FY18 Earnings Guidance www.americanbankingnews.com - May 1 at 9:36 AM
	BRIEF-Catalent Reports Q3 Earnings Per Share Of $0.14 www.reuters.com - May 1 at 9:09 AM
	Catalent Q3 Earnings Outlook finance.yahoo.com - May 1 at 9:09 AM
	Catalent beats by $0.02, beats on revenue seekingalpha.com - May 1 at 9:09 AM
	Catalent: Fiscal 3Q Earnings Snapshot finance.yahoo.com - May 1 at 9:09 AM
	Catalent (CTLT) Receives Average Rating of "Buy" from Brokerages www.americanbankingnews.com - April 25 at 11:19 AM
	Catalent (CTLT) Scheduled to Post Earnings on Wednesday www.americanbankingnews.com - April 25 at 2:56 AM
	Zacks: Brokerages Anticipate Catalent (CTLT) Will Post Quarterly Sales of $610.64 Million www.americanbankingnews.com - April 25 at 2:12 AM
	Analysts Expect Catalent (CTLT) Will Post Earnings of $0.39 Per Share www.americanbankingnews.com - April 23 at 9:20 PM
	Catalent (CTLT) Lowered to "Buy" at BidaskClub www.americanbankingnews.com - April 20 at 12:41 PM
	Catalent, Inc. Announces Third Quarter Fiscal Year 2018 Earnings Conference Webcast finance.yahoo.com - April 16 at 4:41 PM
	Catalent (CTLT) Stock Rating Lowered by BidaskClub www.americanbankingnews.com - April 14 at 5:51 PM
	Catalent (CTLT) Rating Reiterated by Piper Jaffray www.americanbankingnews.com - April 9 at 8:06 PM
	Catalent (CTLT) Stock Rating Lowered by ValuEngine www.americanbankingnews.com - April 8 at 12:54 PM
	$610.64 Million in Sales Expected for Catalent (CTLT) This Quarter www.americanbankingnews.com - April 8 at 1:52 AM
	Analysts Expect Catalent (CTLT) Will Announce Earnings of $0.39 Per Share www.americanbankingnews.com - April 6 at 11:22 PM
	Catalent (CTLT) Lifted to Buy at Zacks Investment Research www.americanbankingnews.com - April 6 at 8:10 PM
	Why Amicus Therapeutics Stock Rose in the Week Ended March 29 finance.yahoo.com - April 3 at 4:46 PM
	Catalent (CTLT) Given Consensus Recommendation of "Buy" by Analysts www.americanbankingnews.com - March 31 at 11:34 AM
	Analysts Set Expectations for Catalent's Q3 2018 Earnings (CTLT) www.americanbankingnews.com - March 30 at 7:04 AM
	'Uniquely Positioned' Catalent Notches KeyBanc Upgrade finance.yahoo.com - March 28 at 4:41 PM
	KeyBanc Upgrades Catalent (CTLT) to Overweight www.streetinsider.com - March 28 at 9:22 AM
	Catalent (CTLT) Lifted to "Overweight" at KeyCorp www.americanbankingnews.com - March 28 at 8:05 AM
	Catalent (CTLT) Upgraded to "Buy" by ValuEngine www.americanbankingnews.com - March 25 at 11:21 AM
	Raymond James Projects 'Rising Momentum' At Catalent Driven By Biologics Expansion finance.yahoo.com - March 22 at 9:21 AM
	Catalent (CTLT) Expected to Post Quarterly Sales of $609.36 Million www.americanbankingnews.com - March 22 at 2:28 AM
	Catalent (CTLT) Rating Increased to Outperform at UBS www.americanbankingnews.com - March 21 at 6:40 PM
	Raymond James Projects 'Rising Momentum' At Catalent Driven By Biologics Expansion - Benzinga www.benzinga.com - March 21 at 4:56 PM
	Raymond James Financial Upgrades Catalent (CTLT) to "Outperform" www.americanbankingnews.com - March 21 at 3:27 PM
	Catalent (CTLT) Downgraded to "Hold" at Zacks Investment Research www.americanbankingnews.com - March 20 at 9:22 PM
	Reviewing Catalent (CTLT) & Histogenics (HSGX) www.americanbankingnews.com - March 14 at 2:07 PM
	Insider Selling: Catalent Inc (CTLT) SVP Sells 9,082 Shares of Stock www.americanbankingnews.com - March 12 at 1:29 PM
	Catalent (CTLT) Downgraded by Zacks Investment Research www.americanbankingnews.com - March 9 at 9:40 PM
	Catalent (CTLT) Upgraded to Buy at Zacks Investment Research www.americanbankingnews.com - March 8 at 8:48 PM
	Biohaven (BHVN) Reports 1st Enrolled Patient in Phase 3 Clinical Trial To Evaluate Rimegepant Zydis ODT www.streetinsider.com - March 7 at 9:15 AM
	Wells Fargo & Company MN Has $29.47 Million Holdings in Catalent Inc (CTLT) www.americanbankingnews.com - March 6 at 3:09 PM
	Catalent Inc (CTLT) Given Consensus Recommendation of "Buy" by Brokerages www.americanbankingnews.com - March 6 at 11:44 AM
	Biohaven Enrolls First Patient In Phase 3 Clinical Trial To Evaluate Rimegepant Zydis® ODT In The Acute Treatment Of Migraine finance.yahoo.com - March 6 at 9:00 AM
	Bank of New York Mellon Corp Purchases 64,561 Shares of Catalent Inc (CTLT) www.americanbankingnews.com - March 5 at 5:00 AM
	Allianz Asset Management GmbH Has $29.12 Million Position in Catalent Inc (CTLT) www.americanbankingnews.com - March 5 at 4:12 AM

Catalent (NYSE:CTLT) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Catalent (NYSE:CTLT) Income Statement, Balance Sheet and Cash Flow Statement

Catalent (NYSE CTLT) Stock Chart for Saturday, May, 26, 2018

Loading chart…

This page was last updated on 5/26/2018 by MarketBeat.com Staff